Theravir, a biotech start-up, was formed to in-license, develop and commercialize new therapeutic based on oncolytic (cancer killing) viruses. Theravir’s first product, the oncolytic virus NDV-HUJ, is a non-engineered virus that causes Newcastle Disease in poultry, but causes only rare mild disease in humans. It is one of the few oncolytic viruses that can be administered intravenously. The virus is expected to be active against a wide range of cancers.

The NDV-HUJ has completed a Phase I/II clinical trial in patients with recurrent glioblastoma brain cancer. The safety and efficacy results obtained in the study indicated that clinical testing should proceed to a Phase II trial. Oncolytic virotherapy is a rapidly emerging therapeutic area with the potential to complement chemotherapy and radiotherapy.

Theravir is based at Hadassah University Medical Center, benefiting from access to academic resources and specialized facilities.